April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Earlier Ocrevus lowers MS progression risk over 10 years Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on the therapy in the controlled part of the trials, compared with…
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). Thatās according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8 Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites Ocrevus (ocrelizumab) had similar benefits in Black and Hispanic multiple sclerosis (MS) patients as earlier clinical trials with white patients did, one-year data from the CHIMES clinical trial indicates. About half of the CHIMES participants achieved no evidence of disease activity, or NEDA, which is defined as the…
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk Undergoing fertility treatment with assistive reproductive technologies does not increase the likelihood of having a relapse for women with multiple sclerosis (MS) who are taking a disease-modifying therapy (DMT), according to a new analysis. “The results are reassurance for women with MS who plan to undergo assistive reproductive…
April 22, 2021 News by Forest Ray PhD #AANAM ā Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā22. GoĀ hereĀ to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’…
September 11, 2020 Columns by Ed Tobias Why a Flu Shot Is More Important Than Ever This Year Labor Day has come and gone here in the U.S. Now, flu season has arrived in the Northern Hemisphere. This isn’t the novel coronavirus we’ve been fighting all year. It’s the regular seasonal flu virus that’s knocking on our door again. Each year, some people with multiple sclerosis (MS)…
May 13, 2020 News by InĆŖs Martins, PhD Ian Duncan Awarded 2020 Dystel Prize for Discoveries in Myelin Repair Neuroscientist Ian D. DuncanĀ has been awarded the 2020 John Dystel Prize for Multiple Sclerosis Research for work that advanced understanding of how myelin, the protective sheath surrounding nerve cells, can be repaired in diseases like multiple sclerosis (MS). āProfessor Duncan has made a series of critical research advances…
September 20, 2019 Columns by Ed Tobias Neuros Say that Flu Shots and Other Vaccines Are OK for Those with MS This is the time of year when my wife and I start thinking about getting our flu shots. We’ve already had the pneumonia and the older shingles vaccine and hope to soon update with the new shingles vaccine, Shingrix (recombinant zoster vaccine). These vaccines are OK with my neurologist and…
September 9, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Cancer Medication Slows MS, Vitamin D and Myelin, Targeting ‘Helper’ T-cells, Vaccination Guidelines Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show Ofatumumab isn’t approved as a multiple sclerosis (MS) treatment. It’s a cancer medication that’s marketed as Arzerra. But in two clinical trials reported here, it did better than Aubagio at treating MS. Its…
August 30, 2019 News by Marisa Wexler, MS New AAN Guidelines Favor Regular Vaccinations, Including Flu Shots, for MS Patients New guidelines from the American Academy of Neurology (AAN) recommend that people with multiple sclerosis (MS) keep up with regular vaccinations, including annual flu shots, but be sure to first advise their doctor on medications they are using. The guidelines were published in the journalĀ Neurology, in the report…
May 17, 2019 News by Ana Pena PhD Out-of-Pocket Costs of MS Treatments in US Soared from 2004-16, Study Finds Out-of-pocket costs for medications treating neurological diseases have skyrocketed over the last 12 years in the U.S., withĀ multiple sclerosis (MS) patients, especially, paying 20 times more in 2016 than they were in 2004, a study reported. “Given the high costs of…
February 15, 2019 News by Larry Luxner Newly Published NMSS Study Confirms Nearly 1 Million Americans Have MS Itās finally official: Around 900,000 Americans and quite possibly more than that have multiple sclerosis (MS) ā easily double the long-accepted figure of 400,000. Since MS News Today first reportedĀ on this finding in November 2017, the National Multiple Sclerosis SocietyĀ (NMSS) study, which reached that conclusion, has…
May 26, 2017 News by Patricia Silva, PhD #CMSC17 – MS Patients Should Contribute to Outcome Measure Development, Study Argues Patients must help develop new outcome measures of multiple sclerosis (MS), since theyĀ and healthcare providers may have differing perceptions of how crucialĀ various measures are, a new study argues. Researchers from the Multiple Sclerosis Center of AtlantaĀ shared this insight today at the Consortium of Multiple Sclerosis Centers (CMSC) 2017 Annual…
March 7, 2017 News by Patricia Silva, PhD Older SPMS Patients More Likely to Suffer from Fatigue, Limited Leg Function, Study Says People with secondary progressive multiple sclerosis (SPMS)Ā are more likely to feel exhausted and haveĀ limited leg function than those without progressive MS as they age, a preliminary study suggests. The findings will be presented atĀ the American Academy of Neurology (AAN) 69th Annual Meeting, set for April 22-28 in Boston.
April 15, 2016 News by Patricia Silva, PhD Teva to Present Pipeline Data on MS Treatments at Ongoing AAN Annual Meeting Teva Pharmaceutical Industries, Ltd., announced that new data on four of its products, including an approved and a potential treatment for multiple sclerosis, will be presented atĀ the 68th Annual Meeting of the American Academy of Neurology (AAN), running through April 21 in Vancouver, Canada. The data, to be…
April 14, 2016 News by admin Array of Multiple Sclerosis Trial Data to Be Presented by Biogen at 2016 AAN Meeting A rangeĀ of new multiple sclerosis (MS) data from Biogen will be revealedĀ atĀ the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15ā21. Presentations will include studies on TecfideraĀ (dimethyl fumarate),Ā one of the most frequently usedĀ oral MS treatments worldwide, as well as several other…
December 16, 2015 News by Patricia Silva, PhD MS Physical Therapy in Need of Proper Study, Experts Say The National Multiple Sclerosis SocietyĀ announced that a panel of expertsĀ led a comprehensive review of 142 published studies addressing rehabilitation in multiple sclerosis (MS), and found evidence suggesting that weekly in-home or outpatient physical therapy offers benefits ā but, mostly, it found a lack of well-designed studies into…
September 1, 2014 News by Patricia Silva, PhD New Multiple Sclerosis Drug May Repair Nerve Demyelination As researchers continue to develop a clearer understanding of the underlying causes ofĀ multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…